Home › Funds › Vestal Point Capital, LP › MYGN

Vestal Point Capital, LP position in MYGN

MYRIAD GENETICS INC · Health Care

Vestal Point Capital, LP reported holding 5,735,000 shares of MYGN (MYRIAD GENETICS INC) in its Q2 2026 13F filing — a position valued at US$32.7M, representing 0.77% of its reported portfolio and ranking #34 among its reported holdings. Vestal Point Capital, LP has disclosed MYGN holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)5.74M sh
Reported value held$32.75M
Portfolio Weight0.77%
First reportedQ3 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's MYGN position evolved

Vestal Point Capital, LP first disclosed a stake in MYGN in Q3 2025 at 600,000 shares (US$4.3M). The position peaked in Q2 2026 at 5,735,000 shares, worth US$32.7M. Across 4 filings, Vestal Point Capital, LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 5,735,000 shares valued at US$32.7M — an increase of 4,087,000 shares quarter over quarter.. Notable position changes include a 104% increase in Q4 2025 (shares fell 27% over the following quarter), a 35% increase in Q1 2026 (shares rose 27% over the following quarter), a 248% increase in Q2 2026 (shares fell 25% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 600.00K $4.34M New
Q4 2025 1.22M $7.52M Add
Q1 2026 1.65M $7.42M Add
Q2 2026 5.74M $32.75M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MYGN and 13F data

MYGN (MYRIAD GENETICS INC) is a Health Care company. 19 other funds we track also report a position in MYGN. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MYGN

No other tracked fund reports a position in MYGN.

All MYGN fund holders →

FAQ

How long has Vestal Point Capital, LP held MYGN?

Vestal Point Capital, LP has disclosed MYGN holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is Vestal Point Capital, LP's current position in MYGN?

As of Q2 2026, Vestal Point Capital, LP holds 5.74M shares of MYGN (MYRIAD GENETICS INC), valued at $32.75M, representing 0.77% of its reported portfolio and ranking #34.

Has Vestal Point Capital, LP been buying or selling MYGN?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP increased its position in MYGN. The position peaked in Q2 2026 at 5.74M shares.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.